Remedium Bio, a Boston-area gene therapy company developing treatments for a range of large clinical unmet needs in rheumatology, endocrinology, and age-related diseases, and Biovian Oy, a globally operating Nordic CDMO for biopharmaceuticals, have agreed …
Biovian is looking forward to participating in the BIO International Convention on June 13th-16th in San Diego. #BIO2022 is back in person. Biovian representatives, CBO Magnus Gustafsson and Head of Business Development Eero Mustalahti are …
Viral contaminations are rare events in biopharmaceutical manufacturing, but regulatory agencies expect all biologics to undergo viral clearance testing to mitigate the risk of contamination [1, 2]. Therapies based on viral vectors have a small …
ANLBIO, a biotechnology company developing gene therapies for neurodegenerative diseases, has selected Biovian Oy as a CDMO partner. The agreement covers process development for ANLBIO’s proprietary gene therapy vector, ANL-101, followed by 200 L scale …
New Horizons 2021 event took place on December 9th in Stockholm. Dr. Magnus Gustafsson from Biovian gave a talk about “Gene therapy today and tomorrow.” New Horizons is an international educational forum that focuses on …
Here we present some basic concepts of Viral Vectors used in gene therapy applications with special focus on AAV and Adenovirus vectors. Please proceed to this page if you are looking for information about our …
Announcements about job openings have been frequent at Biovian, since the company is growing steadily. Thus, several persons have been hired during the last few months. We asked Eija Martikkala, one of our newest colleagues, …
GEN, one of the biggest biotech magazines interviewed Biovian about the critical bottlenecks in Adeno-associated virus (AAV) Manufacturing. AAVs, gene therapy and manufacturing technologies are two of the “hottest” biotech areas in the industry right …
Adeno-associated virus (AAV) has emerged as the most flexible and useful vector for gene therapy. With hundreds of gene therapy trials ongoing, safe and efficient production of AAV is absolutely critical. In this roundtable discussion, …
The article discusses the challenges small and mid-sized companies are facing when taking AAV vector-based innovations from the laboratory bench to the clinic. While in-house manufacturing may be an option for some companies, partnering with a …